Adma Biologics reported $29.75M in Operating Profit for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Adma Biologics ADMA:US USD 29.75M 39.06M
Agile Therapeutics AGRX:US USD -6878000 11.83M
Alnylam Pharmaceuticals ALNY:US USD -188614000 146.01M
Biocryst Pharmaceuticals BCRX:US USD -46311000 28.87M
Dynavax Technologies DVAX:US USD 63.14M 1.74M
Minerva Neurosciences NERV:US USD -5070000 137K
Novavax NVAX:US USD -243879000 116.69M
Omeros OMER:US USD -40138000 10.63M
Takeda 4502:JP JPY 146.99B 42.55B